Blockchain for Clinical Trial Management
Sector: Tertiary sector · Industry: Pharmaceutical sales and services · Organisation: Pfizer · Maturity level: Concept
Pfizer explores the use of blockchain technology to improve integrity and transparency in clinical trials. The technology enables secure management of electronic patient consent, tamper-proof storage of research data, and increased auditability of the entire study process. Pfizer is already part of IBM's Food Trust Blockchain network and works with other pharmaceutical companies on blockchain solutions for supply chain transparency.
Documentation status
- Project status: Concept
- Evidence: Evidence medium
- Editorial review: Ufuk Avci, 15 April 2026
Description
Clinical trials have several critical integrity issues that undermine scientific reproducibility and trust in pharmaceutical research. Blockchain-based study management systems address these structurally.
The main problems of clinical trials: (1) Protocol changes: primary endpoints can be changed after data review — HARKing (Hypothesising After Results are Known). (2) Selective publication: negative results are less frequently published. (3) Data falsification: individual data points can be manipulated in central systems. Blockchain solves all three: the study protocol is anchored on the blockchain before the study begins (timestamp); each patient consent is digitally signed and stored immutably; all data entries have cryptographic timestamps. Triall (Netherlands) is a specialised clinical trial platform used as primary data governance in over 8,000 studies. Embleema (USA, PMC article describes the approach) offers blockchain-based clinical research with direct FDA engagement: the FDA-approved infrastructure accelerates the regulatory approval process. Regulatory: FDA 21 CFR Part 11 (Electronic Records) and EMA Guideline on Computerised Systems require verifiable audit trails — blockchain is the natural answer.
Perspectives
B2B — organisations perspective
Pharmaceutical companies and CROs can automatically generate FDA/EMA-compliant audit trails with blockchain-based study management, shorten study durations, and structurally exclude the risk of subsequent protocol changes.
B2C — consumers perspective
Patients gain more transparency about the use of their data and can precisely track their consent. Increased data integrity leads to more trustworthy study results and ultimately to safer medicines.
Employees perspective
Staff in clinical trials experience less manual documentation effort through automated blockchain logging. Researchers can focus more on the actual study work while administrative processes are digitised.
Benefits
General
- Tamper-proof storage of all study data increases regulators' trust and accelerates approval processes.
- Transparent logging of all patient consents and data changes reduces regulatory risks.
- Decentralised study architecture enables a global participant base and more efficient recruitment of study participants.
B2B — organisations
- Reduced compliance costs through automated and immutable documentation of all regulatory requirements.
B2C — consumers
- Increased transparency about the use of personal health data strengthens patients' trust in clinical trials.
Employees
- Automated data logging reduces manual documentation work and allows focus on the actual research activity.
Challenges
General
- Integration with existing clinical study management systems requires significant technical adjustments and investments.
- Regulatory recognition of blockchain-based study data is not yet fully established in all jurisdictions.
B2B — organisations
- High implementation costs for blockchain infrastructure and staff training can disadvantage smaller pharmaceutical companies.
Employees
- Required technical training for blockchain technology can cause resistance among established researchers.
Technology foundation
Blockchain technology creates an immutable digital ledger in which all transactions and data changes are permanently recorded. This feature makes it ideal for clinical trials, as it enables tamper-proof records of patient consents, study results, and data modifications.
Implementation examples
Pfizer IBM Food Trust Blockchain Partnership
Pfizer wanted to increase transparency in the medicine supply chain and combat counterfeit drugs. Blockchain technology enables seamless tracking of medicines throughout the entire supply chain.
Pfizer is part of IBM’s Food Trust Blockchain network to enhance the traceability of medicines.
Pfizer is working as part of the IBM Food Trust Blockchain network to improve the traceability of medicines from manufacturer to patient. The company collaborates with other pharmaceutical giants such as Merck and GlaxoSmithKline to develop blockchain solutions for supply chain transparency. The project aims to combat counterfeit medicines and ensure regulatory compliance.
The project addresses the challenges of medicine counterfeiting and lack of transparency in complex global supply chains. Blockchain enables an immutable record of all transactions and movements of medicines.
Tags
Clinical Trials, Data Integrity, Transparency, Patient Consent, Regulatory Compliance